Breast cancer is the second leading cause of cancer deaths among women. The
development of breast cancer is a multi-step process involving multiple cell types, and its …

Over the past 2 decades, there has been an extraordinary progress in the regimens
developed for the treatment of human epidermal growth factor receptor 2 (HER2)-positive …

Many cancer therapies produce toxic side effects whose molecular mechanisms await full
elucidation. The most feared and studied side effect of chemotherapeutic drugs is …

Purpose Fusions that involve neurotrophic-tropomyosin receptor kinase (NTRK) genes are
known drivers of oncogenesis. Therapies that target these ultra-rare, constitutionally active …

Purpose Clinical evidence demonstrating the effectiveness of systemic therapy for advanced
salivary duct carcinoma (SDC) is lacking because of the disease's rarity. We assessed the …

Highlights•The treatment landscape of MBC has progressively widened in the last
years.•Several therapeutic strategies proved to be capable of prolonging survival of patients …

Background Breast cancer is a leading cause of death for women worldwide, with incidence
increasing in lower-income countries. For patients with human epidermal growth factor …

Ziele Das Ziel dieser offiziellen Leitlinie, die von der Deutschen Gesellschaft für
Gynäkologie und Geburtshilfe (DGGG) und der Deutschen Krebsgesellschaft (DKG) …

Growing evidence suggests a clear role of the host immune system in HER2+ breast cancer.
In addition, HER2+ breast cancer is generally considered more immunogenic than hormone …

Highlights•Monoclonal antibodies are effective treatment for various cancers and
autoimmune diseases.•Immune checkpoint therapy in cancer has emerged as a potent …